🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As a cancer patient, I would rather have aa additional eye (AI) looking at my pathology and reading my scans than just two human eyes. Things are missed!

Savolitinib + osimertinib shows ORR (58% vs 16%), DoR (11.8 vs 4.5 mo), and PFS (8.3 vs 3.6 mo) vs. savolitinib + placebo in EGFRm NSCLC w/ MET alteration (overexpression +/- amplification) post-osi. Promising CNS activity & manageable safety. Next: SAFFRON Phase 3. #ASCO25

Not a very impressive ORR

We now definitely know who owns ABC News (and CBS too): ABC News Suspends Terry Moran Over X Post That Called Trump Official Stephen Miller A “World-Class Hater” deadline.com/2025/06/abc-ne…

#breathtakingmoments w/ my grandson

The EGFR Resisters June Newsletter is here: ASCO 2025 Research Highlights, New Project PRIORITY Dashboard, and news from our community! Read it here: mailchi.mp/89bd739b1435/b…

#breathtakingmoment in Uzbekistan. Was on my bucket list!

If your time has value, then so does ours. And if our ideas are critical enough to shape your work, they’re critical enough to budget for -This powerful piece by Christine Von Raesfeld is spot on, and so relatable bit.ly/3ZH04cS Many of us have sat on advisory boards,

As a patient, it may be better than docetaxel but still meh. We need a higher bar.

this woke me up!!!! When is aumolertinib coming to US and how does it rank in same realm with other TKIs???

Thank you, AnnabelleGurwitch for advocating for chronically ill and cancer patients who get financially gaslighted by healthcare insurers, PBMs and the like. Make it right!!ilcn.org/patient-perspe…

Thank you for doing all you do. This disease is relentless and needs better treatments. Research is key! 💔

We need Medicare to approve AI as a 2nd eye in medical imaging.

This is shameful and NOT beautiful! Donald J. Trump & Republicans are destroying our country and putting all its people at risk.

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study Adding chemo to osimertinib may benefit patients w/ EGFR + TP53 (L858R) more than those w/ Exon 19 del nature.com/articles/s4159…

Lung cancer research is so disappointing after TKIs. No effective vaccines, immunotherapy, and lots of toxic ADCs. Please start thinking out of the box! This from an EGFR NSCLC patient!!

Hello, I just wanted to let everyone know that Libby's book is now available on Amazon and Kindle. We also have some remaining hard copy versions of the book available on eBay (let me know if anyone is interested in the hard copy version and I'll send you the eBay link). I

Honored to be an Expert Judge Mentor for #EGFRSummit! Submit your abstracts by 8/8 to be part of the next class of EGFR Resisters Research Summit Young Investigators! ➡️ ce.ceconcepts.com/EGFR2025CFA #EGFR #LCSM #MedTwitter #MedEd

Calling all #thoracic #oncology leaders! We’re inviting early career investigators to submit an abstract for a chance to join us at the 7th Annual EGFR Resisters Research Summit EGFR Resisters Research Summit, (Nov 6–8 in Chicago). Please share this opportunity with your fellows, postdocs, or

At NOSCM, Julia Rotow MD presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled